8-K: Tilray Brands Achieves Record Q1 Revenue, Net Income

Tilray Brands reports strong first quarter fiscal 2026 results, achieving record Q1 net revenue of $210 million and net income, alongside significant balance sheet strengthening.

Summary

• Achieved record Q1 net revenue of $209.5 million, representing a 5% increase compared to the prior year period.
• Reported net income of $1.5 million, a significant improvement from a net loss of $(34.7) million in the first quarter of fiscal 2025.
• Adjusted EBITDA increased 9% year-over-year to $10.2 million.
• Net cash used in operations improved significantly by $34.0 million, reducing to $(1.3) million from $(35.3) million.
• Canadian Adult-Use Cannabis gross revenue increased 12%, maintaining the #1 market position and expanding market share.
• International Cannabis revenue grew 10% year-over-year.
• Strengthened the balance sheet with $264.8 million in cash and marketable securities.
• Reduced net debt to $4 million, resulting in a net debt to trailing twelve months adjusted EBITDA ratio of 0.07x.
• Reiterated Fiscal Year 2026 Adjusted EBITDA outlook of $62 million to $72 million.

Sentiment

Score: 8

Explanation: The company demonstrated strong financial improvements, including record revenue, a return to net income, significant cash flow improvement, and substantial debt reduction. The positive outlook on market opportunities, particularly in cannabis rescheduling, further enhances the positive sentiment, despite some gross margin compression.

Positives

• Record Q1 net revenue of $209.5 million, a 5% increase year-over-year.
• Achieved net income of $1.5 million, a substantial improvement from a net loss of $(34.7) million in the prior year.
• Adjusted EBITDA increased 9% to $10.2 million.
• Net cash used in operations improved significantly by $34.0 million, reducing to $(1.3) million.
• Canadian Adult-Use Cannabis gross revenue increased 12%, maintaining the #1 market position and expanding market share.
• International Cannabis revenue grew 10% year-over-year.
• Balance sheet strengthened with $264.8 million in cash and marketable securities.
• Net debt reduced to $4 million, resulting in a net debt to trailing twelve months adjusted EBITDA ratio of 0.07x.
• Operating income improved significantly to $2.092 million from a loss of $(36.570) million in the prior year.
• Total outstanding debt reduced by $7.7 million in the first quarter.

Negatives

• Gross profit decreased to $57.5 million from $59.7 million, a 4% decline year-over-year.
• Gross margin decreased to 27% from 30% in the prior year.
• Cannabis gross profit decreased to $23.3 million from $24.2 million.
• Cannabis gross margin decreased to 36% from 40%.
• Beverage net revenue slightly decreased to $55.7 million from $56.0 million.
• Beverage gross profit decreased to $21.3 million from $22.9 million.
• Beverage gross margin decreased to 38% from 41%.
• Distribution gross margin decreased to 11% from 12%.
• Net cash used in operating activities remained negative at $(1.3) million.
• Free cash flow was negative at $(10.571) million.
• Adjusted free cash flow was negative at $(4.758) million.

Risks

• The Company's ability to become a leading lifestyle consumer packaged goods company.
• The Company's ability to become a leading beverage alcohol company.
• The Company's ability to achieve long-term profitability.
• The Company's ability to achieve operational scale, market share, distribution, profitability, and revenue growth in particular business lines and markets.
• The Company's ability to successfully achieve revenue growth, margin and profitability improvements, production and supply chain efficiencies, synergies, and cost savings.
• The Company's ability to achieve fiscal year 2026 financial guidance, including expected Adjusted EBITDA of $62 million to $72 million and synergy optimizations.
• Expected revenue growth, sales volume, profitability, synergies, and accretion related to any of its acquisitions.
• Expected opportunities in the U.S., including upon U.S. federal cannabis legalization or rescheduling.
• The Company's ability to successfully leverage artificial intelligence strategies.
• The Company's anticipated investments and acquisitions, including in organic and strategic growth, partnership efforts, product offerings, and other initiatives.
• The Company's ability to commercialize new and innovative products.
• Many factors could cause actual results, performance, or achievement to be materially different from any forward-looking statements.
• Other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements.

Future Outlook

Management is confident in Tilray's ability to seize transformative opportunities, especially as the U.S. explores cannabis rescheduling and the European cannabis landscape continues to evolve. The company reiterated its Fiscal Year 2026 Adjusted EBITDA outlook of $62 million to $72 million and is committed to expanding access, advancing innovation, and supporting responsible regulatory progress globally.

Management Comments

• "As we enter fiscal 2026, Tilray's first quarter results underscore the effectiveness of our strategic vision and disciplined execution. Achieving a record Q1 net revenue of $210 million, delivering net income, and fortifying our balance sheet are not just milestones, they are proof points of our commitment to building sustainable growth, operational excellence, and unlocking value for our shareholders."
• "Our global platform positions Tilray Brands not just to participate in, but to lead, the evolution of the global cannabis, beverage, and wellness sectors."
• "Looking forward, I am confident in Tilray's ability to seize the transformative opportunities ahead, especially as the U.S. explores cannabis rescheduling and the European cannabis landscape continues to evolve."
• "Our global platform, proven expertise in medical and adult-use cannabis, and trusted partnerships with patients, healthcare professionals, and policymakers set us apart as the partner of choice in this dynamic industry."
• "These achievements and forward trends reinforce my unwavering belief in Tilray's trajectory and our ability to deliver long-term value to our investors."

Industry Context

Tilray Brands operates at the intersection of the cannabis, beverage, and wellness industries, positioning itself as a leader in these evolving sectors. The company's strategic focus is heavily influenced by potential U.S. cannabis rescheduling and the ongoing evolution of the European cannabis market, indicating a proactive approach to regulatory changes and market expansion. Its established global platform and expertise in both medical and adult-use cannabis are highlighted as key competitive advantages in a dynamic and rapidly changing industry landscape.

Comparison to Industry Standards

• Tilray Brands maintains the #1 position in Canadian Adult-Use Cannabis revenue and is expanding its market share within this segment.

Stakeholder Impact

• Shareholders: Potential for increased value due to improved financial performance, strategic positioning for future growth, and a strengthened balance sheet.
• Customers: Continued expansion of cannabis offerings and market share in Canadian adult-use and international markets suggests broader product availability and choice.
• Employees: Focus on operational efficiencies and strategic growth may lead to organizational adjustments or new opportunities within the expanding global platform.

Next Steps

• Continue to build sustainable growth, operational excellence, and unlock value for shareholders.
• Seize transformative opportunities related to potential U.S. cannabis rescheduling and the evolving European cannabis landscape.
• Expand access, advance innovation, and support responsible regulatory progress around the world.
• Host a live audio webcast on October 9, 2025, at 8:30 a.m. Eastern Time to discuss these results.

Key Dates

Recommendation

Tilray Brands has demonstrated a significant financial turnaround in Q1 Fiscal 2026, achieving record net revenue, returning to net income, and substantially improving cash flow from operations. The company's balance sheet has been significantly strengthened through debt reduction and a healthy cash position. Its leadership in the Canadian adult-use cannabis market and growth in international cannabis revenue, coupled with a reiterated positive Adjusted EBITDA outlook for FY26, indicate strong operational execution. The strategic positioning to capitalize on potential U.S. cannabis rescheduling and the evolving European market presents substantial future growth opportunities, making Tilray Brands an attractive investment for long-term growth.

Keywords

Cannabis, Beverage, Wellness, Tilray Brands, Financial Results, Q1 2026, Net Revenue, Net Income, Adjusted EBITDA, Canadian Adult-Use Cannabis, International Cannabis, Balance Sheet, Debt Reduction, SEC Filing, TLRY